Adelaide Research & Scholarship
Statistics
Total Visits
| Views | |
|---|---|
| Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study(legacy) | 114 |
| Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study(legacy) | 84 |
Total Visits per Month
| October 2023 | November 2023 | December 2023 | January 2024 | February 2024 | March 2024 | April 2024 | |
|---|---|---|---|---|---|---|---|
| Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study | 1 | 6 | 3 | 1 | 3 | 2 | 0 |
File Downloads
| Views |
|---|
Top Country Views
| Views | |
|---|---|
| United States | 52 |
| China | 21 |
| Australia | 15 |
| France | 12 |
| Germany | 9 |
| Netherlands | 8 |
| Vietnam | 8 |
| Spain | 2 |
| Bangladesh | 1 |
| Brazil | 1 |
Top City Views
| Views | |
|---|---|
| Ashburn | 19 |
| Kaleen | 12 |
| Hanoi | 8 |
| Rotterdam | 8 |
| Fairfield | 7 |
| Beijing | 6 |
| Zhengzhou | 5 |
| Changchun | 3 |
| Des Moines | 3 |
| Madrid | 2 |